Abbott Laboratories (ABT) said Friday clinical data from two late-breaking presentations demonstrated the safety and efficacy of its minimally invasive ablation catheters for treating atrial fibrillation.

Data from the study showed the Volt pulsed field ablation system achieved an 84.2% freedom from documented rhythm recurrence at 12 months in patients with paroxysmal atrial fibrillation. In patients with persistent atrial fibrillation, nearly 68% remained free from an additional episode following treatment, according to the company.

Abbott said the single-arm study also found fewer therapy applications per vein, a repeat ablation rate of less than 6%, and significant improvements in patient-reported quality of life scores.

The company also reported new data from a trial evaluating its sensor-enabled TactiFlex duo ablation catheter in more complex atrial fibrillation cases.

Six-month data showed an 81% freedom from documented rhythm recurrence in paroxysmal atrial fibrillation patients, along with improved quality of life scores, the company said.

Price: 109.66, Change: +0.57, Percent Change: +0.52